AbbVie Just Bet Big on a Robot Chemist Backed by Nvidia
AbbVie just signed a multi-year AI drug discovery deal with Nvidia-backed Iambic Therapeutics, and the timing (same day as Iambic's IPO filing) says everything. Here's why Big Pharma's AI bets are no longer experiments.
The Pharma Giant Wants a Shortcut
Drug discovery is brutally slow. The average small-molecule drug takes over a decade to go from a chemist's whiteboard to a patient's medicine cabinet, and most candidates never make it at all. So when a company like AbbVie, one of the biggest pharma players on Earth, signs a multi-year deal with an AI startup to speed things up, it's worth paying attention.
On September 21, AbbVie announced a multi-year collaboration with Iambic Therapeutics, an AI-native drug discovery company backed by Nvidia and the Qatar Investment Authority. The goal: use Iambic's artificial intelligence platform to find and design new small-molecule drugs across immunology, neuroscience, and oncology.
Neither company disclosed the financial terms (classic), but the structure follows a familiar playbook: Iambic gets an upfront payment plus success-based milestones and tiered royalties on any drugs that eventually reach the market. Translation: AbbVie pays a little now and a lot later, but only if the AI actually delivers.
What Iambic Actually Does
If traditional drug discovery is like searching for a needle in a haystack by hand, Iambic's approach is more like using a metal detector, a magnet, and thermal imaging all at once.
The company's platform, called Enchant (now on version 3), is a closed-loop system. That means its AI models don't just predict which molecules might work; they connect directly to automated labs that make, test, and refine compounds in real time. The AI designs a molecule, the robot lab builds it, scientists test it, and the results feed back into the model to improve the next round. Rinse and repeat, dramatically faster than the old way.
Iambic also uses a tool called NeuralPLexer, which predicts how proteins and drug molecules physically fit together. Think of it as a 3D puzzle solver that can test billions of combinations before a single molecule is ever synthesized.
The company isn't just selling promises, either. It already has three internal drug programs in development:
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
IAM1363, a brain-penetrant HER2 inhibitor for certain cancers, currently in Phase 1/1b clinical testing with early signs of anti-tumor activity
IAM217, a KIF18A inhibitor being developed for ovarian cancer and triple-negative breast cancer, now in IND-enabling studies (the last step before asking regulators for permission to test in humans)
IAM-C1, a CDK2/4 inhibitor targeting hormone receptor-positive breast cancer, also in IND-enabling studies
So the platform isn't theoretical. It's producing real drug candidates that are moving through the pipeline.
Why AbbVie Needs This
AbbVie has been on a strategic AI spending spree, and this Iambic deal is the latest chapter.
In December 2023, AbbVie signed an AI antibody discovery deal with BigHat Biosciences worth $30 million upfront and up to roughly $325 million in milestones. It also partnered with ConcertAI and Caris Life Sciences on precision medicine, and struck a deal with Gilgamesh Pharmaceuticals (psychedelic-inspired drug development, of all things) that could be worth up to $1.95 billion in total milestones.
Internally, AbbVie has been building what it calls AI@AbbVie, an enterprise-wide approach to weaving artificial intelligence into how it discovers, develops, and delivers medicines. The company also runs an R&D Convergence Hub called ARCH that's designed to integrate AI into its core research operations.
The pattern is clear: AbbVie would rather partner with specialized AI companies than try to build everything in-house. It's the "hire the expert" approach, and it lets AbbVie tap into cutting-edge platforms while keeping its financial risk contained through milestone-based deal structures.
Iambic's Investors Tell Their Own Story
Iambic's investor list reads like a who's-who of smart money betting on AI infrastructure.
The company raised about $53 million in its 2021 Series A. It followed up with roughly $100 million in a 2023 Series B. Then came a $50 million round in April 2024 that brought in the Qatar Investment Authority, followed by another $65 million tranche later that year. In November 2025, Iambic closed an oversubscribed round of more than $100 million.
By the time of the AbbVie announcement, Iambic had raised approximately $462 million in capital since inception, plus $74.7 million from collaboration partners, totaling about $536.5 million in aggregate gross cash.
Oh, and one more thing: Iambic filed for a U.S. IPO on the same day it announced the AbbVie deal. Coincidence? About as coincidental as wearing your best suit to a first date.
The Bigger Picture: AI Has Left the Chat(bot) Phase
This deal isn't happening in a vacuum. The entire pharma industry is racing to lock in AI discovery partnerships, and the pace is accelerating fast.
One 2026 industry tally counted 114 AI/ML discovery partnerships in 2025, up from 84 the year before. Lilly is working with Insilico and Superluminal. Novartis partnered with Relation Therapeutics. Takeda signed its own multi-year deal with Iambic earlier in 2026 (focused on oncology and GI/inflammation). Pfizer expanded collaborations with PostEra and Chai Discovery. Even Nvidia itself has partnered directly with Lilly and Thermo Fisher on compute and lab automation.
The shift is unmistakable. Two years ago, pharma companies treated AI like a science fair experiment: interesting, maybe promising, definitely not something you'd bet the pipeline on. Now? These deals are multi-year, they carry hundreds of millions in potential payouts, and they're targeting real therapeutic areas with real commercial ambitions.
The question is no longer "can AI help discover drugs?" It's "which AI platform becomes a permanent part of how pharma does R&D?"
What to Watch
Analysts aren't treating the AbbVie-Iambic deal as an immediate earnings mover. It's a long-term R&D bet, and the payoffs (if they come) are years away.
But a few things are worth tracking. First, watch Iambic's IPO: the AbbVie partnership gives it serious credibility heading into public markets, and the timing was clearly intentional. Second, keep an eye on whether any of Iambic's internal programs (especially IAM1363, which is already in clinical trials) generate meaningful data. Positive results would validate the platform in a way that no partnership announcement ever could.
And third, watch the broader competitive landscape. When every major pharma company is signing AI discovery deals, the ones who picked the best platforms will have a real edge. The ones who didn't will have expensive press releases and not much else.
AbbVie is placing its chips. Now we wait to see if the robot chemist delivers.
6 min read
The $3.9 Million Shot That Could Save Kids With No Other Options
For decades, families with Sanfilippo syndrome were told to take their kids home and love them. Now a $3.9 million gene therapy from Ultragenyx is the first FDA-approved treatment for this fatal childhood brain disease, and it's part of a wave that's reshaping rare disease medicine.
